MAIA Biotechnology Inc.(MAIA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MAIA MAIA Biotechnology Inc.

Post-Mkt 01-16 18:38:30 EST

1.74

+0.15

+9.43%

盘后1.82

+0.08+4.60%

18:37 EST

High1.89	Low1.60	Vol2.42M
Open1.60	D1 Closing1.59	Amplitude18.24%
Mkt Cap64.44M	Tradable Cap49.31M	Total Shares37.03M
T/O4.23M	T/O Rate8.53%	Tradable Shares28.34M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MAIA","market":"US","secType":"STK","nameCN":"MAIA Biotechnology Inc.","latestPrice":1.74,"timestamp":1768597200000,"preClose":1.59,"halted":0,"volume":2416320,"hourTrading":{"tag":"盘后","latestPrice":1.82,"preClose":1.74,"latestTime":"18:37 EST","volume":16301,"amount":29182.066500999998,"timestamp":1768606668906},"delay":0,"floatShares":28340000,"shares":37032307,"eps":-0.768287,"marketStatus":"Post-Mkt","change":0.15,"latestTime":"01-16 18:38:30 EST","open":1.6,"high":1.89,"low":1.6,"amount":4233760.162272,"amplitude":0.18239,"askPrice":1.97,"askSize":100,"bidPrice":1.72,"bidSize":20,"shortable":3,"etf":0,"ttmEps":-0.768287,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1768611600000},"marketStatusCode":4,"adr":0,"listingDate":1659067200000,"exchange":"AMEX","adjPreClose":1.59,"preHourTrading":{"tag":"盘前","latestPrice":1.6607,"preClose":1.59,"latestTime":"09:29 EST","volume":26458,"amount":42983.4763024,"timestamp":1768573742817},"postHourTrading":{"tag":"盘后","latestPrice":1.82,"preClose":1.74,"latestTime":"18:37 EST","volume":16301,"amount":29182.066500999998,"timestamp":1768606668906},"volumeRatio":5.993027},"requestUrl":"/m/hq/s/MAIA/wiki","defaultTab":"wiki","newsList":[{"id":"2603850656","title":"MAIA Biotechnology Highlights Strategy in New Investor Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2603850656","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603850656?lang=en_us&edition=fundamental","pubTime":"2026-01-14 06:48","pubTimestamp":1768344530,"startTime":"0","endTime":"0","summary":"An update from MAIA Biotechnology, Inc. ( ($MAIA) ) is now available. On January 13, 2026, MAIA Biotechnology, Inc. filed and published a set of in...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/maia-biotechnology-highlights-strategy-in-new-investor-presentation?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/maia-biotechnology-highlights-strategy-in-new-investor-presentation?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MAIA","BK4139"],"gpt_icon":0},{"id":"2602543866","title":"Director Stan Smith Reports Acquisition of Maia Biotechnology Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2602543866","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602543866?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:44","pubTimestamp":1768225499,"startTime":"0","endTime":"0","summary":"Stan Smith, Director of Maia Biotechnology Inc., reported the acquisition of common shares of Maia Biotechnology Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maia Biotechnology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 12, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL79tlWW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Director Stan Smith Reports Acquisition of Maia Biotechnology Inc. Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAIA","BK4139"],"gpt_icon":0},{"id":"2593147221","title":"MAIA Biotechnology Board Members Continue to Participate in Private Placement Financings","url":"https://stock-news.laohu8.com/highlight/detail?id=2593147221","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593147221?lang=en_us&edition=fundamental","pubTime":"2025-12-24 21:01","pubTimestamp":1766581260,"startTime":"0","endTime":"0","summary":"Purchases reflect strong confidence in the scientific differentiation and commercial potential of ateganosine CHICAGO, Dec.  24, 2025  (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/24/3210313/0/en/MAIA-Biotechnology-Board-Members-Continue-to-Participate-in-Private-Placement-Financings.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2487616109.SGD","BK4585","BK4107","BK4588","BK4139","L","MAIA","LU0053666078.USD","LU0210528500.USD"],"gpt_icon":0},{"id":"2593186524","title":"Director Stan Smith Reports Acquisition of Maia Biotechnology Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2593186524","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593186524?lang=en_us&edition=fundamental","pubTime":"2025-12-23 21:19","pubTimestamp":1766495973,"startTime":"0","endTime":"0","summary":"Stan Smith, Director, reported an acquisition of common shares of Maia Biotechnology Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maia Biotechnology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 23, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nNDL5Dk2VS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAIA","BK4139"],"gpt_icon":0},{"id":"2593418394","title":"Director Ngar Yee Louie Acquires Common Shares of Maia Biotechnology Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2593418394","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593418394?lang=en_us&edition=fundamental","pubTime":"2025-12-23 21:15","pubTimestamp":1766495720,"startTime":"0","endTime":"0","summary":"Ngar Yee Louie, a Director at Maia Biotechnology Inc., has reported the acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maia Biotechnology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 23, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nNDL7wD6gS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Director Ngar Yee Louie Acquires Common Shares of Maia Biotechnology Inc","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAIA","BK4139"],"gpt_icon":0},{"id":"2592930351","title":"MAIA Biotechnology Announces $1.51 Million Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2592930351","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592930351?lang=en_us&edition=fundamental","pubTime":"2025-12-17 05:15","pubTimestamp":1765919700,"startTime":"0","endTime":"0","summary":"CHICAGO, IL, Dec.  16, 2025  (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/16/3206621/0/en/MAIA-Biotechnology-Announces-1-51-Million-Private-Placement.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAIA","BK4139"],"gpt_icon":0},{"id":"2590154348","title":"MAIA’s Ateganosine Surges Ahead with Breakthrough Momentum as Pivotal Phase 3 Trial Initiates","url":"https://stock-news.laohu8.com/highlight/detail?id=2590154348","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590154348?lang=en_us&edition=fundamental","pubTime":"2025-12-12 02:00","pubTimestamp":1765476000,"startTime":"0","endTime":"0","summary":"CHICAGO, Dec.  11, 2025  (GLOBE NEWSWIRE) -- Ateganosine (THIO, 6-thio-2'-deoxyguanosine), a first-in-class telomere-targeting therapy under development by MAIA Biotechnology (NYSE American: MAIA), ap","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/11/3204217/0/en/MAIA-s-Ateganosine-Surges-Ahead-with-Breakthrough-Momentum-as-Pivotal-Phase-3-Trial-Initiates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAIA","BK4139"],"gpt_icon":0},{"id":"2590511840","title":"Maia Biotechnology Announces First Patient Dosed in Thio-104 Phase 3 Pivotal Trial Evaluating Ateganosine as Third-Line Treatment for Advanced Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2590511840","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590511840?lang=en_us&edition=fundamental","pubTime":"2025-12-11 22:00","pubTimestamp":1765461602,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nTUA3HFJZN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MAIA"],"gpt_icon":0},{"id":"2590516848","title":"Maia Biotechnology Executives Acquire 182,445 Shares in Insider Buying Spree","url":"https://stock-news.laohu8.com/highlight/detail?id=2590516848","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590516848?lang=en_us&edition=fundamental","pubTime":"2025-12-11 21:00","pubTimestamp":1765458041,"startTime":"0","endTime":"0","summary":"Maia Biotechnology Inc. announced that CEO Dr. Vlad Vitoc and other board members have acquired approximately 182,445 shares of the company in open-market purchases between November 21 and 28, 2025. This latest round of insider buying reflects continued confidence in the company's strategy and the potential of its telomere-targeting cancer therapy, ateganosine. Directors and Officers now collectively hold 4,480,120 shares, representing 12.95% of the company.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maia Biotechnology Inc. published the original content used to generate this news brief via GlobeNewswire  on December 11, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL2Lz6Y4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU2210150020.SGD","MAIA","SG9999014013.SGD","LU2095319765.USD","IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4588","SG9999014039.USD","SG9999014005.SGD","NDAQ","LU2210149790.SGD","BK4585","SG9999014021.USD","BK4112","BK4139"],"gpt_icon":0},{"id":"2590324095","title":"Maia Biotechnology Unveils Breakthrough Telomere-Targeting Therapy for Resistant Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2590324095","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590324095?lang=en_us&edition=fundamental","pubTime":"2025-12-11 03:00","pubTimestamp":1765393212,"startTime":"0","endTime":"0","summary":"Maia Biotechnology Inc. announced promising scientific developments for its lead candidate, ateganosine, a telomere-targeting agent designed for patients with advanced non-small cell lung cancer  who are resistant to current immunotherapies and chemotherapies. The company highlighted that ateganosine's dual mechanism targets telomeres to directly induce cancer cell death while also stimulating the immune system's response. Maia recently received Fast Track Designation from the U.S. FDA for ateganosine in this patient population and is initiating the Phase 3 THIO-104 trial. The company also noted that ateganosine holds FDA Orphan Drug Designations for glioblastoma and hepatocellular carcinoma. Research results and further data will be presented in the future as the clinical trial progresses.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is f","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nNDLc6fPHz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","SG9999014013.SGD","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","LU0314104364.USD","LU2210150020.SGD","MAIA","IE00B64PRP62.GBP","SG9999014005.SGD","BK4585","BK4139","LU2095319765.USD","SG9999014021.USD","BK4588","LU2210149790.SGD","BK4112","IE00BKPKM429.USD","SG9999014039.USD"],"gpt_icon":0},{"id":"2590240483","title":"Director Stan Smith Reports Acquisition of Maia Biotechnology Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2590240483","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590240483?lang=en_us&edition=fundamental","pubTime":"2025-12-10 05:51","pubTimestamp":1765317118,"startTime":"0","endTime":"0","summary":"Stan Smith, Director of Maia Biotechnology Inc., reported the acquisition of common shares of Maia Biotechnology Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maia Biotechnology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 09, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nNDL6r5Jkb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Director Stan Smith Reports Acquisition of Maia Biotechnology Inc. Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MAIA"],"gpt_icon":0},{"id":"2588730867","title":"BRIEF-Maia Biotechnology Announces Open Market Purchases By CEO And Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2588730867","media":"Reuters","labels":["executive","shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588730867?lang=en_us&edition=fundamental","pubTime":"2025-12-01 22:18","pubTimestamp":1764598691,"startTime":"0","endTime":"0","summary":"BRIEF-Maia Biotechnology Announces Open Market Purchases By CEO And DirectorsDec 1 (Reuters) - Maia Biotechnology Inc MAIA.A:MAIA BIOTECHNOLOGY ANNOUNCES OPEN MARKET PURCHASES BY CEO AND DIRECTORSMAIA","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nTUA9VSMFT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MAIA"],"gpt_icon":0},{"id":"2588773741","title":"Maia Biotechnology Announces Open Market Purchases by CEO and Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2588773741","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588773741?lang=en_us&edition=fundamental","pubTime":"2025-12-01 22:17","pubTimestamp":1764598620,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nTUA9VSMFT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MAIA","BK4139"],"gpt_icon":0},{"id":"2588744773","title":"Maia Biotechnology Inc - CEO Vlad Vitoc Purchases 94,300 Shares at $1.08 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2588744773","media":"THOMSON REUTERS","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588744773?lang=en_us&edition=fundamental","pubTime":"2025-12-01 22:17","pubTimestamp":1764598620,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nTUA9VSMFT:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MAIA"],"gpt_icon":0},{"id":"2588737497","title":"Maia Biotechnology Inc - Board Members Purchase 88,145 Shares at $1.04 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2588737497","media":"THOMSON REUTERS","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588737497?lang=en_us&edition=fundamental","pubTime":"2025-12-01 22:17","pubTimestamp":1764598620,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nTUA9VSMFT:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MAIA","BK4139"],"gpt_icon":0},{"id":"2588721639","title":"Director Stan Smith Reports Acquisition of Common Shares in Maia Biotechnology Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2588721639","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588721639?lang=en_us&edition=fundamental","pubTime":"2025-12-01 19:15","pubTimestamp":1764587734,"startTime":"0","endTime":"0","summary":"Stan Smith, Director, has reported the acquisition of common shares of Maia Biotechnology Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maia Biotechnology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 01, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDL4x4DLk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Director Stan Smith Reports Acquisition of Common Shares in Maia Biotechnology Inc","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAIA","BK4139"],"gpt_icon":0},{"id":"2587075677","title":"CEO’s Bold Move: Major Stock Purchase at MAIA Biotechnology!","url":"https://stock-news.laohu8.com/highlight/detail?id=2587075677","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587075677?lang=en_us&edition=fundamental","pubTime":"2025-11-29 10:02","pubTimestamp":1764381739,"startTime":"0","endTime":"0","summary":"New insider activity at MAIA Biotechnology, Inc. ( ($MAIA) ) has taken place on November 28, 2025. CEO Vlad Vitoc has made a significant move by pu...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/ceos-bold-move-major-stock-purchase-at-maia-biotechnology-insider-trading-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/ceos-bold-move-major-stock-purchase-at-maia-biotechnology-insider-trading-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MAIA","BK4139"],"gpt_icon":0},{"id":"2586781650","title":"Director Cristian Luput Acquires Common Shares of Maia Biotechnology Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2586781650","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586781650?lang=en_us&edition=fundamental","pubTime":"2025-11-28 19:52","pubTimestamp":1764330756,"startTime":"0","endTime":"0","summary":"Cristian Luput, Director at Maia Biotechnology Inc., has reported the acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maia Biotechnology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 28, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251128:nNDL66ZGD0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Director Cristian Luput Acquires Common Shares of Maia Biotechnology Inc","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAIA","BK4139"],"gpt_icon":0},{"id":"2586684208","title":"Sarawak to Host the Inaugural Asia Pacific Aerospace Conference & Exhibition (APACE 2026) at BCCK","url":"https://stock-news.laohu8.com/highlight/detail?id=2586684208","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586684208?lang=en_us&edition=fundamental","pubTime":"2025-11-28 12:22","pubTimestamp":1764303720,"startTime":"0","endTime":"0","summary":"KUCHING, Malaysia, Nov. 28, 2025 /PRNewswire/ -- The Ministry of Education, Innovation and Talent Development Sarawak , in collaboration with Borneo Business Connect Sdn Bhd and supported by Business Events Sarawak , today announced the launch of the inaugural Asia Pacific Aerospace Conference & Exhibition . The event will take place from 27–29 January 2026 at the Borneo Convention Centre Kuching .APACE 2026 is a strategic initiative of the Sarawak State Government to position Sarawak as a rising hub for aerospace, aviation, and advanced technology within Southeast Asia. Held under the theme \"Navigating the Future of Aerospace: Innovation, Sustainability and Growth,\" the event is designed to catalyse international collaboration and connect global aerospace stakeholders, industry leaders, innovators, and educational institutions with the rapidly expanding opportunities emerging across the region.Hosted by MEITD, APACE 2026 is strongly supported by multiple ministries and agencies, inclu","market":"fut","thumbnail":"https://mma.prnewswire.com/media/2833984/DSC02345.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2833984/DSC02345.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/sarawak-to-host-the-inaugural-asia-pacific-aerospace-conference--exhibition-apace-2026-at-bcck-302627880.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EPU","SMA","BK4217","SDEC","BK4082","BK4218","MAIA","HST","MOTS","BK4181","BK4139","BK4585","BK4588"],"gpt_icon":0},{"id":"2586529817","title":"Maia Biotechnology Director Stan Smith Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2586529817","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586529817?lang=en_us&edition=fundamental","pubTime":"2025-11-27 05:44","pubTimestamp":1764193473,"startTime":"0","endTime":"0","summary":"Stan Smith, Director of Maia Biotechnology Inc., reported the acquisition of common shares of Maia Biotechnology Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maia Biotechnology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 26, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nNDL52Ztxq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Maia Biotechnology Director Stan Smith Reports Acquisition of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAIA","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.maiabiotech.com","stockEarnings":[{"period":"1week","weight":-0.0422},{"period":"1month","weight":0.2927},{"period":"3month","weight":0.2422},{"period":"6month","weight":-0.0592},{"period":"1year","weight":-0.2639},{"period":"ytd","weight":0.0392}],"compareEarnings":[{"period":"1week","weight":0.004},{"period":"1month","weight":0.0197},{"period":"3month","weight":0.0419},{"period":"6month","weight":0.103},{"period":"1year","weight":0.1678},{"period":"ytd","weight":0.0151}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. MAIA Biotechnology, Inc. was incorporated in 2018 and is headquartered in Chicago, Illinois.","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.151736},{"month":2,"riseRate":0,"avgChangeRate":-0.060346},{"month":3,"riseRate":0.333333,"avgChangeRate":0.091126},{"month":4,"riseRate":0.666667,"avgChangeRate":0.190738},{"month":5,"riseRate":0.666667,"avgChangeRate":0.134126},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.131471},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.058081},{"month":8,"riseRate":0,"avgChangeRate":-0.148704},{"month":9,"riseRate":0.25,"avgChangeRate":0.000086},{"month":10,"riseRate":0.25,"avgChangeRate":-0.039628},{"month":11,"riseRate":0.25,"avgChangeRate":-0.189158},{"month":12,"riseRate":0.5,"avgChangeRate":0.077797}],"exchange":"AMEX","name":"MAIA Biotechnology Inc.","nameEN":"MAIA Biotechnology Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"MAIA Biotechnology Inc.(MAIA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest MAIA Biotechnology Inc.(MAIA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"MAIA Biotechnology Inc.,MAIA,MAIA Biotechnology Inc.股票,MAIA Biotechnology Inc.股票老虎,MAIA Biotechnology Inc.股票老虎国际,MAIA Biotechnology Inc.行情,MAIA Biotechnology Inc.股票行情,MAIA Biotechnology Inc.股价,MAIA Biotechnology Inc.股市,MAIA Biotechnology Inc.股票价格,MAIA Biotechnology Inc.股票交易,MAIA Biotechnology Inc.股票购买,MAIA Biotechnology Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"MAIA Biotechnology Inc.(MAIA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest MAIA Biotechnology Inc.(MAIA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}